Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immix BiopharmaIMMX +3.80%22 EV-to-OCF is -19.27 as of Aug. 23, 2026. GuruFocus rates IMMX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Immix Biopharma ranks better than 80.84% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Immix Biopharma's Enterprise Value is $741.71 Mil.
Immix Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-38.50 Mil. Therefore, Immix Biopharma's EV-to-OCF for today is -19.27.
The historical rank and industry rank for Immix Biopharma's EV-to-OCF or its related term are showing as below:
IMMX'
s EV-to-OCF Range Over the Past 10 Years
Min: -19.27 Med: 0 Max: -19.27
Current: -19.27
During the past 7 years, the highest EV-to-OCF of Immix Biopharma was -19.27. The lowest was -19.27. And the median was .
IMMX's EV-to-OCF is ranked better than 80.84% of 1409
companies
in the Biotechnology industry
Industry Median: -3.68
vs IMMX: -19.27
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Immix Biopharma's PE Ratio (TTM) for today is calculated as:
Immix Biopharma's share price for today is $13.665.
Immix Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Immix Biopharma EV-to-OCF Related Terms
Immix Biopharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Immix Biopharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immix Biopharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immix Biopharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immix Biopharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Immix Biopharma's EV-to-OCF falls into.
Immix Biopharma's current Enterprise Value is $741.71 Mil.
Immix Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immix Biopharma (IMMX) has a EV-to-OCF of -19.27 as of Aug. 23, 2026. According to the industry distribution chart, Immix Biopharma ranks #270 out of 1409 companies in the Biotechnology industry, placing it in the top 19.2%.
Is Immix Biopharma's EV-to-OCF too high?
Immix Biopharma's current EV-to-OCF is -19.27. Based on the distribution chart, Immix Biopharma ranks #270 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immix Biopharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Immix Biopharma's EV-to-OCF compare to CBIO and NVCT?
According to the Biotechnology industry distribution chart, Immix Biopharma ranks #270 out of 1409 companies for EV-to-OCF. This places Immix Biopharma in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Immix Biopharma's current EV-to-OCF is -19.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immix Biopharma stock overvalued right now?
Immix Biopharma (IMMX) has a current EV-to-OCF of -19.27. The current EV-to-OCF is -19.27. Immix Biopharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Immix Biopharma (IMMX), the current EV-to-OCF is -19.27 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
22GF Score
Get the complete analysis for IMMX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMX has been successfully added to your 
